NLRP3 inflammasomes pathway: a key target for Metformin

Abad-Jiménez Z, López-Domènech S, Díaz-Rúa R, Iannantuoni F, Gómez-Abril S, Periañez-Gómez D et al (2020) Systemic oxidative stress and visceral adipose tissue mediators of NLRP3 inflammasome and autophagy are reduced in obese Type 2 Diabetic patients treated with metformin. Antioxidants (Basel). https://doi.org/10.3390/antiox9090892CrossRefPubMed

Abdul-Sater AA, Philpott DJ (2016) Inflammasomes. In: MJH Ratcliffe (Ed.), Encyclopedia of immunobiology (pp. 447–453). Oxford: Academic Press. https://doi.org/10.1016/B978-0-12-374279-7.10020-7

Adeghate J, Nurulain S, Tekes K, Feher E, Kalasz H, Adeghate E (2017) Novel biological therapies for the treatment of diabetic foot ulcers. Expert Opin Biol Ther 17(8):979–987. https://doi.org/10.1080/14712598.2017.1333596CrossRefPubMed

Adeneye AA, Benebo AS (2007) Oral metformin-ascorbic acid co-administration ameliorates alcohol-induced hepatotoxicity in rats. Nig Q J Hosp Med 17(4):155–159. https://doi.org/10.4314/nqjhm.v17i4.12698CrossRefPubMed

Al-Sheikh M, Akil H, Pfau M, Sadda SR (2016) Swept-source OCT angiography imaging of the foveal avascular zone and macular capillary network density in diabetic retinopathy. Invest Ophthalmol vis Sci 57(8):3907–3913PubMedCrossRef

Alzokaky AA, Al-Karmalawy AA, Saleh MA, Abdo W, Farage AE, Belal A et al (2023) Metformin ameliorates doxorubicin-induced cardiotoxicity targeting HMGB1/TLR4/NLRP3 signaling pathway in mice. Life Sci 316:121390. https://doi.org/10.1016/j.lfs.2023.121390CrossRefPubMed

Atas N, Eroglu GA, Sodan HN, Ozturk BO, Babaoglu H, Satis H, et al (2021) Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients. Clin Exp Rheumatol 39 Suppl 132(5):30–36. https://doi.org/10.55563/clinexprheumatol/815tdt

Bagheri H, Ghasemi F, Barreto GE, Rafiee R, Sathyapalan T, Sahebkar A (2020) Effects of curcumin on mitochondria in neurodegenerative diseases. BioFactors 46(1):5–20. https://doi.org/10.1002/biof.1566CrossRefPubMed

Baldwin AS Jr (2001) Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107(1):3–6. https://doi.org/10.1172/JCI11891CrossRefPubMedPubMedCentral

Bando S, Fukuda D, Soeki T, Nishimoto S, Uematsu E, Matsuura T et al (2015) Expression of NLRP3 in subcutaneous adipose tissue is associated with coronary atherosclerosis. Atherosclerosis 242(2):407–414. https://doi.org/10.1016/j.atherosclerosis.2015.07.043CrossRefPubMed

Bhansali S, Bhansali A, Dutta P, Walia R, Dhawan V (2020) Metformin upregulates mitophagy in patients with T2DM: a randomized placebo-controlled study. J Cell Mol Med 24(5):2832–2846. https://doi.org/10.1111/jcmm.14834CrossRefPubMedPubMedCentral

Blevins HM, Xu Y, Biby S, Zhang S (2022) The NLRP3 Inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci 14:879021. https://doi.org/10.3389/fnagi.2022.879021CrossRefPubMedPubMedCentral

Bonen A, Jain SS, Snook LA, Han X-X, Yoshida Y, Buddo KH et al (2015) Extremely rapid increase in fatty acid transport and intramyocellular lipid accumulation but markedly delayed insulin resistance after high fat feeding in rats. Diabetologia 58:2381–2391PubMedCrossRef

Bradburn MJ, Clark TG, Love SB, Altman DG (2003) Survival analysis Part III: multivariate data analysis–choosing a model and assessing its adequacy and fit. Br J Cancer 89(4):605–611PubMedPubMedCentralCrossRef

Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ et al (2005) Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146(12):5341–5349PubMedCrossRef

Bullón P, Alcocer-Gómez E, Carrión AM, Marín-Aguilar F, Garrido-Maraver J, Román-Malo L et al (2016) AMPK phosphorylation modulates pain by activation of NLRP3 inflammasome. Antioxid Redox Signal 24(3):157–170. https://doi.org/10.1089/ars.2014.6120CrossRefPubMedPubMedCentral

Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beall C et al (2016) Anti-inflammatory effects of metformin irrespective of Diabetes status. Circ Res 119(5):652–665. https://doi.org/10.1161/circresaha.116.308445CrossRefPubMedPubMedCentral

Cao J, Peng Q (2022) NLRP3 inhibitor tranilast attenuates gestational diabetes mellitus in a genetic mouse model. Drugs R D 22(1):105–112. https://doi.org/10.1007/s40268-022-00382-7CrossRefPubMedPubMedCentral

Chan P, Shao L, Tomlinson B, Zhang Y, Liu ZM (2018) Metformin transporter pharmacogenomics: insights into drug disposition-where are we now? Expert Opin Drug Metab Toxicol 14(11):1149–1159. https://doi.org/10.1080/17425255.2018.1541981CrossRefPubMed

Chen F, Wei G, Xu J, Ma X, Wang Q (2018a) Naringin ameliorates the high glucose-induced rat mesangial cell inflammatory reaction by modulating the NLRP3 Inflammasome. BMC Complem Altern Med 18(1):1–11CrossRef

Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J et al (2018b) Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 9(6):7204–7218. https://doi.org/10.18632/oncotarget.23208CrossRefPubMed

Chen L, Lv L, Zhang L, Gao Z, Liu Y, Wang S et al (2021) Metformin ameliorates bladder dysfunction in a rat model of partial bladder outlet obstruction. Am J Physiol Renal Physiol 320(5):F838-f858. https://doi.org/10.1152/ajprenal.00625.2020CrossRefPubMed

Chen XC, Wu D, Wu HL, Li HY, Yang C, Su HY et al (2022) Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway. Lupus Sci Med. https://doi.org/10.1136/lupus-2021-000611CrossRefPubMedPubMedCentral

Chen Y, Ye X, Escames G, Lei W, Zhang X, Li M et al (2023) The NLRP3 inflammasome: contributions to inflammation-related diseases. Cell Mol Biol Lett 28(1):51. https://doi.org/10.1186/s11658-023-00462-9CrossRefPubMedPubMedCentral

Coll RC, Schroder K, Pelegrín P (2022) NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci 43(8):653–668. https://doi.org/10.1016/j.tips.2022.04.003CrossRefPubMed

Committee ADAPP (2024) 9 Pharmacologic approaches to glycemic treatment: standards of care in Diabetes—2025. Diabetes Care 48(Supplement_1): S181-S206. https://doi.org/10.2337/dc25-S009

Cui F-Q, Tang L, Gao Y-B, Wang Y-F, Meng Y, Shen C et al (2019) Effect of Baoshenfang formula on podocyte injury via inhibiting the NOX-4/ROS/p38 pathway in diabetic nephropathy. J Diabetes Res. https://doi.org/10.1155/2019/2981705CrossRefPubMedPubMedCentral

Czyzyk A, Tawecki J, Sadowski J, Ponikowska I, Szczepanik Z (1968) Effect of biguanides on intestinal absorption of glucose. Diabetes 17(8):492–498PubMedCrossRef

Dai B, Wu Q, Zeng C, Zhang J, Cao L, Xiao Z et al (2016) The effect of Liuwei Dihuang decoction on PI3K/Akt signaling pathway in liver of Type 2 Diabetes mellitus (T2DM) rats with insulin resistance. J Ethnopharmacol 192:382–389. https://doi.org/10.1016/j.jep.2016.07.024CrossRefPubMed

Das B, Sarkar C, Rawat VS, Kalita D, Deka S, Agnihotri A (2021) Promise of the NLRP3 inflammasome inhibitors in in vivo disease models. Molecules. https://doi.org/10.3390/molecules26164996CrossRefPubMedPubMedCentral

Ding Y, Jia Y, Song Y, Lu C, Li Y, Chen M et al (2014) The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects. Eur J Clin Pharmacol 70(2):141–146. https://doi.org/10.1007/s00228-013-1604-7CrossRefPubMed

Ding S, Xu S, Ma Y, Liu G, Jang H, Fang J (2019) Modulatory mechanisms of the NLRP3 inflammasomes in diabetes. Biomolecules 9(12):850PubMedPubMedCentralCrossRef

Divers J, Mayer-Davis EJ, Lawrence JM, Isom S, Dabelea D, Dolan L et al (2020) Trends in incidence of type 1 and type 2 diabetes among youths—selected counties and Indian reservations, United States, 2002–2015. Morb Mortal Wkly Rep 69(6):161CrossRef

Docrat TF, Nagiah S, Chuturgoon AA (2021) Metformin protects against neuroinflammation through integrated mechanisms of miR-141 and the NF-ĸB-mediated inflammasome pathway in a diabetic mouse model. Eur J Pharmacol 903:174146. https://doi.org/10.1016/j.ejphar.2021.174146CrossRefPubMed

Du RW, Bu WG (2020) Metformin improves depressive-like symptoms in mice via inhibition of peripheral and central NF-κB-NLRP3 inflammation activation. Exp Brain Res 238(11):2549–2556. https://doi.org/10.1007/s00221-020-05911-xCrossRefPubMed

Du G, Xie W, Su Y, Ma Y, Gao X, Jiang S et al (2020) Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study. PeerJ 8:e9905. https://doi.org/10.7717/peerj.9905CrossRefPubMedPubMedCentral

Duncan JG (2011) Mitochondrial dysfunction in diabetic cardiomyopathy. Biochimica et Biophysica Acta (BBA) Mol Cell Res1813(7):1351–1359

El-Arabey AA, Abdalla M (2020) Metformin and COVID-19: a novel deal of an old drug. J Med Virol 92(11):2293–2294. https://doi.org/10.1002/jmv.25958CrossRefPubMedPubMedCentral

El-Arabey AA, Abdalla M, Ali Eltayb W (2019) Metformin: ongoing journey with superdrug revolution. Adv Pharm Bull 9(1):1–4. https://doi.org/10.15171/apb.2019.001CrossRefPubMedPubMedCentral

El-Arabey AA, Abdalla M, Rashad Abd-Allah A, Marenga HS, Modafer Y, Aloufi AS (2023a) Molecular dynamic and bioinformatic studies of metformin-induced ACE2 phosphorylation in the presence of different SARS-CoV-2 S protein mutations. Saudi J Biol Sci 30(7):103699. https://doi.org/10.1016/j.sjbs.2023.103699CrossRefPubMedPubMedCentral

El-Arabey AA, Zhang H, Abdalla M, Al-Shouli ST, Alkhalil SS, Liu Y (2023b) Metformin as a promising target for DPP4 expression: computational modeling and experimental validation. Med Oncol 40(10):277. https://doi.org/10.1007/s12032-023-02140-4CrossRefPubMedPubMedCentral

El-Haggar SM, Hegazy SK, Maher MM, Bahgat MM, Bahaa MM (2024) Repurposing metformin as adjuvant therapy in patients with ulcerative colitis treated with mesalamine: a randomized controlled double-blinded study. Int Immunopharmacol 138:112541. https://doi.org/10.1016/j.intimp.2024.112541CrossRefPubMed

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D et al (2022) 2 classification and diagnosis of diabetes: standards of care in diabetes—2023. Diabetes Care 46(Supplement_1):S19–S40. https://doi.org/10.2337/dc23-S002

Eslami SS, Jafari D, Montazeri H, Sadeghizadeh M, Tarighi P (2021) Combination of curcumin and metformin inhibits cell growth and induces apoptosis without affecting the cell cycle in LNCaP prostate cancer cell line. Nutr Cancer 73(6):1026–1039. https://doi.org/10.1080/01635581.2020.1783327CrossRefPubMed

Fei Q, Ma H, Zou J, Wang W, Zhu L, Deng H et al (2020) Metformin protects against ischaemic myocardial injury by alleviating autophagy-ROS-NLRP3-mediated inflammatory response in macrophages. J Mol Cell Cardiol 145:1–13. https://doi.org/10.1016/j.yjmcc.2020.05.016CrossRefPubMed

Flory J, Lipska K (2019) Metformin in 2019. JAMA 321(19):1926–1927. https://doi.org/10.1001/jama.2019.3805CrossRefPubMedPubMedCentral

Forbes JM, Cooper ME (2013) Mechanisms of diabetic complications. Physiol Rev 93(1):137–188PubMedCrossRef

Gao TH, Liao W, Lin LT, Zhu ZP, Lu MG, Fu CM et al (2022) Curcumae rhizoma and its major constituents against hepatobiliary disease: Pharmacotherapeutic properties and potential clinical applications. Phytomedicine 102:154090. https://doi.org/10.1016/j.phymed.2022.154090CrossRefPubMed

Głombik K, Trojan E, Kurek A, Budziszewska B, Basta-Kaim A (2019) Inflammatory consequences of maternal diabetes on the offspring brain: a hippocampal organotypic culture study. Neurotox Res 36(2):357–375. https://doi.org/10.1007/s12640-019-00070-6CrossRefPubMedPubMedCentral

Goldberger JJ, Arora R, Buckley U, Shivkumar K (2019) Autonomic nervous system dysfunction: JACC focus seminar. J Am Coll Cardiol 73(10):1189–1206PubMedPubMedCentralCrossRef

Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE (2012) Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacog Genom 22(11):820–827. https://doi.org/10.1097/FPC.0b013e3283559b22CrossRef

Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, Castro R et al (2014) Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 96(3):370–379. https://doi.org/10.1038/clpt.2014.109CrossRefPubMed

Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK et al (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50(2):81–98. https://doi.org/10.2165/11534750-000000000-00000CrossRefPubMed

Gulsin GS, Athithan L, McCann GP (2019) Diabetic cardiomyopathy: prevalence, determinants and potential treatments. Therapeut Adv Endocrinol Metabol 10:2042018819834869CrossRef

Guo H, Pan C, Chang B, Wu X, Guo J, Zhou Y et al (2016) Triptolide improves diabetic nephropathy by regulating Th cell balance and macrophage infiltration in rat models of diabetic nephropathy. Exp Clin Endocrinol Diabetes 124(06):389–398PubMedCrossRef

Guo QJ, Shan J, Xu YF, Hu YY, Huo CL, Song JY et al (2020) Pioglitazone metformin complex improves polycystic ovary syndrome comorbid psychological distress via inhibiting NLRP3 inflammasome activation: a prospective clinical study. Mediators Inflamm 2020:3050487. https://doi.org/10.1155/2020/3050487CrossRefPubMedPubMedCentral

Han F, Xue M, Chang Y, Li X, Yang Y, Sun B et al (2017) Triptolide suppresses glomerular mesangial cell proliferation in diabetic nephropathy is associated with inhibition of PDK1/Akt/mTOR pathway. Int J Biol Sci 13(10):1266PubMedPubMedCentralCrossRef

Han YC, Tang SQ, Liu YT, Li AM, Zhan M, Yang M et al (2021) AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice. Cell Death Dis 12(10):925. https://doi.org/10.1038/s41419-021-04184-8CrossRefPubMedPubMedCentral

Hao J, Li Y, Li R (2013) A novel mechanism of NALP3 inducing ischemia reperfusion injury by activating MAPK pathway in acute renal failure. Med Hypotheses 80(4):463–465PubMedCrossRef

Hasanzadeh S, Read MI, Bland AR, Majeed M, Jamialahmadi T, Sahebkar A (2020) Curcumin: an inflammasome silencer. Pharmacol Res 159:104921. https://doi.org/10.1016/j.phrs.2020.104921CrossRefPubMed

He L, Wondisford FE (2015) Metformin action: concentrations matter. Cell Metab 21(2):159–162. https://doi.org/10.1016/j.cmet.2015.01.003CrossRefPubMed

Hermann L (1979) Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metabol 5(3):233–245

Hölscher ME, Bode C, Bugger H (2016) Diabetic cardiomyopathy: does the type of diabetes matter? Int J Mol Sci 17(12):2136PubMedPubMedCentralCrossRef

Homme RP, Singh M, Majumder A, George AK, Nair K, Sandhu HS et al (2018) Remodeling of retinal architecture in diabetic retinopathy: disruption of ocular physiology and visual functions by inflammatory gene products and pyroptosis. Front Physiol 9:1268PubMedPubMedCentralCrossRef

Hu M, Yuan X, Liu Y, Tang S, Miao J, Zhou Q et al (2017) IL-1beta-induced NF-kappaB activation down-regulates miR-506 expression to promotes osteosarcoma cell growth through JAG1. Biomed Pharmacother 95:1147–1155. https://doi.org/10.1016/j.biopha.2017.08.120CrossRefPubMed

Jankauskas SS, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A et al (2021) Heart failure in diabetes. Metabolism 125:154910PubMedPubMedCentralCrossRef

Jia G, DeMarco VG, Sowers JR (2016) Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol 12(3):144–153PubMedCrossRef

Jia G, Whaley-Connell A, Sowers JR (2018) Diabetic cardiomyopathy: a hyperglycaemia-and insulin-resistance-induced heart disease. Diabetologia 61(1):21–28PubMedCrossRef

Jia Y, Cui R, Wang C, Feng Y, Li Z, Tong Y et al (2020) Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway. Redox Biol 32:101534. https://doi.org/10.1016/j.redox.2020.101534CrossRefPubMedPubMedCentral

Jia W, Bai T, Zeng J, Niu Z, Fan D, Xu X et al (2021) Combined administration of metformin and atorvastatin attenuates diabetic cardiomyopathy by inhibiting inflammation, apoptosis, and oxidative Stress in Type 2 diabetic mice. Front Cell Dev Biol 9:634900. https://doi.org/10.3389/fcell.2021.634900CrossRefPubMedPubMedCentral

Jiang Q, Liu P, Wu X, Liu W, Shen X, Lan T et al (2011) Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-κB signaling pathway. Mol Cell Endocrinol 331(1):34–40PubMedCrossRef

Jin L, Jin F, Guo S, Liu W, Wei B, Fan H et al (2022) Metformin inhibits NLR family pyrin domain containing 3 (NLRP)-relevant Neuroinflammation via an adenosine-5’-monophosphate-activated protein kinase (AMPK)-dependent pathway to alleviate early brain injury after subarachnoid hemorrhage in mice. Front Pharmacol 13:796616. https://doi.org/10.3389/fphar.2022.796616CrossRefPubMedPubMedCentral

Kahkhaie KR, Mirhosseini A, Aliabadi A, Mohammadi A, Mousavi MJ, Haftcheshmeh SM et al (2019) Curcumin: a modulator of inflammatory signaling pathways in the immune system. Inflammopharmacology 27(5):885–900. https://doi.org/10.1007/s10787-019-00607-3CrossRefPubMed

Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Andréjak M, Lalau JD (2016) Unexpectedly long half-life of metformin elimination in cases of metformin accumulation. Diabet Med 33(1):105–110. https://doi.org/10.1111/dme.12959CrossRefPubMed

Kanto K, Ito H, Noso S, Babaya N, Hiromine Y, Taketomo Y et al (2017) Effects of dosage and dosing frequency on the efficacy and safety of high-dose metformin in Japanese patients with Type 2 diabetes mellitus. J Diabetes Investig 9(3):587–593. https://doi.org/10.1111/jdi.12755CrossRefPubMedPubMedCentral

Kaufmann FN, Costa AP, Ghisleni G, Diaz AP, Rodrigues ALS, Peluffo H et al (2017) NLRP3 inflammasome-driven pathways in depression: clinical and preclinical findings. Brain Behav Immun 64:367–383. https://doi.org/10.1016/j.bbi.2017.03.002CrossRefPubMed

Kelley N, Jeltema D, Duan Y, He Y (2019) The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. https://doi.org/10.3390/ijms20133328CrossRefPubMedPubMedCentral

Kingsbury SR, Conaghan PG, McDermott MF (2011) The role of the NLRP3 inflammasome in gout. J Inflamm Res 4:39–49. https://doi.org/10.2147/jir.S11330CrossRefPubMedPubMedCentral

Kuan IHS, Wilson LC, Leishman JC, Cosgrove S, Walker RJ, Putt TL et al (2021) Metformin doses to ensure efficacy and safety in patients with reduced kidney function. PLoS One 16(2):e0246247. https://doi.org/10.1371/journal.pone.0246247CrossRefPubMedPubMedCentral

Kursawe R, Dixit VD, Scherer PE, Santoro N, Narayan D, Gordillo R et al (2016) A role of the inflammasome in the low storage capacity of the abdominal subcutaneous adipose tissue in obese adolescents. Diabetes 65(3):610–618. https://doi.org/10.2337/db15-1478CrossRefPubMed

Kusuhara S, Fukushima Y, Ogura S, Inoue N, Uemura A (2018) Pathophysiology of diabetic retinopathy: the old and the new. Diabetes Metab J 42(5):364–376PubMedPubMedCentralCrossRef

Lan Z, Tan F, He J, Liu J, Lu M, Hu Z et al (2024) Curcumin-primed olfactory mucosa-derived mesenchymal stem cells mitigate cerebral ischemia/reperfusion injury-induced neuronal PANoptosis by modulating microglial polarization. Phytomedicine 129:155635. https://doi.org/10.1016/j.phymed.2024.155635CrossRefPubMed

Lebeche D, Davidoff AJ, Hajjar RJ (2008) Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med 5(11):715–724PubMedCrossRef

Leonard CE, Han X, Brensinger CM, Bilker WB, Cardillo S, Flory JH et al (2018) Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: a retrospective cohort study. Pharmacoepidemiol Drug Saf 27(1):9–18. https://doi.org/10.1002/pds.4337CrossRefPubMed

Li A, Zhang S, Li J, Liu K, Huang F, Liu B (2016) Metformin and resveratrol inhibit Drp1-mediated mitochondrial fission and prevent ER stress-associated NLRP3 inflammasome activation in the adipose tissue of diabetic mice. Mol Cell Endocrinol 434:36–47. https://doi.org/10.1016/j.mce.2016.06.008CrossRefPubMed

Li X, Li Z, Li B, Zhu X, Lai X (2019) Klotho improves diabetic cardiomyopathy by suppressing the NLRP3 inflammasome pathway. Life Sci 234:116773PubMedCrossRef

Li JY, Zhao CC, Peng JF, Zhang M, Wang L, Yin G et al (2022) The protective effect of Sheng Mai Yin on diabetic cardiomyopathy via NLRP3/caspase-1 pathway. Evid Based Complem Alternat Med 2022:1234434. https://doi.org/10.1155/2022/1234434CrossRef

Li W, Liu X, Liu Z, Xing Q, Liu R, Wu Q et al (2024) The signaling pathways of selected traditional Chinese medicine prescriptions and their metabolites in the treatment of diabetic cardiomyopathy: a review. Front Pharmacol 15:1416403. https://doi.org/10.3389/fphar.2024.1416403CrossRefPubMedPubMedCentral

Lian F, Ni Q, Shen Y, Yang S, Piao C, Wang J et al (2020) International traditional Chinese medicine guideline for diagnostic and treatment principles of diabetes. Ann Palliat Med 9(4):2237–2250. https://doi.org/10.21037/apm-19-271CrossRefPubMed

Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389(24):2221–2232. https://doi.org/10.1056/NEJMoa2307563CrossRefPubMed

Liu B, Yu J (2021) Anti-NLRP3 inflammasome natural compounds: an update. Biomedicines. https://doi.org/10.3390/biomedicines9020136CrossRefPubMedPubMedCentral

Liu J, Yao C, Wang Y, Zhao J, Luo H (2023) Non-drug interventions of traditional Chinese medicine in preventing Type 2 diabetes: a review. Chin Med 18(1):151. https://doi.org/10.1186/s13020-023-00854-1CrossRefPubMedPubMedCentral

Lu L, Lu Q, Chen W, Li J, Li C, Zheng Z (2018) Vitamin D3 protects against diabetic retinopathy by inhibiting high-glucose-induced activation of the ROS/TXNIP/NLRP3 inflammasome pathway. J Diabetes Res

Luan P, Zhuang J, Zou J, Li H, Shuai P, Xu X et al (2018) NLRC5 deficiency ameliorates diabetic nephropathy through alleviating inflammation. FASEB J 32(2):1070–1084PubMedCrossRef

Luo B, Li B, Wang W, Liu X, Liu X, Xia Y et al (2014a) Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc Drugs Ther 28:33–43PubMedCrossRef

Luo B, Li B, Wang W, Liu X, Xia Y, Zhang C et al (2014b) NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One 9(8):e104771PubMedPubMedCentralCrossRef

Luo B, Huang F, Liu Y, Liang Y, Wei Z, Ke H et al (2017) NLRP3 inflammasome as a molecular marker in diabetic cardiomyopathy. Front Physiol 8:519PubMedPubMedCentralCrossRef

Lv Z, Guo Y (2020) Metformin and its benefits for various diseases. Front Endocrinol (Lausanne) 11:191. https://doi.org/10.3389/fendo.2020.00191CrossRefPubMed

Machado Júnior PAB, Lass A, Pilger BI, Fornazari R, Moraes TP, Pinho RA (2024) SGLT2 inhibitors and NLRP3 inflammasome: potential target in diabetic kidney disease. J Bras Nefrol 46(4):e20230187. https://doi.org/10.1590/2175-8239-JBN-2023-0187enCrossRefPubMed

Marx N, Husain M, Lehrke M, Verma S, Sattar N (2022) GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with Type 2 diabetes. Circulation 146(24):1882–1894. https://doi.org/10.1161/CIRCULATIONAHA.122.059595CrossRefPubMed

Mary Rebecca Y, Sudha V, Bharathiraja T, Kannan T, Lavanya J, Hemanth Kumar AK (2023) Urinary excretion of metformin in diabetic patients with and without tuberculosis. Indian J Tubercul 70(1):37–41. https://doi.org/10.1016/j.ijtb.2022.03.004CrossRef

Matthaei S, Greten H (1991) Evidence that metformin ameliorates cellular insulin-resistance by potentiating insulin-induced translocation of glucose transporters to the plasma membrane. Diabete Metab 17(1 Pt 2):150–158PubMed

Mohamed EK, Hafez DM (2023) Gallic acid and metformin co-administration reduce oxidative stress, apoptosis and inflammation via Fas/caspase-3 and NF-κB signaling pathways in thioacetamide-induced acute hepatic encephalopathy in rats. BMC Complem Med Ther 23(1):265. https://doi.org/10.1186/s12906-023-04067-9CrossRef

Mulay SR (2019) Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases. Kidney Int 96(1):58–66PubMedCrossRef

Nabrdalik K, Skonieczna-Żydecka K, Irlik K, Hendel M, Kwiendacz H, Łoniewski I et al (2022) Gastrointestinal adverse events of metformin treatment in patients with Type 2 diabetes mellitus: a systematic review, meta-analysis and meta-regression of randomized controlled trials. Front Endocrinol (Lausanne) 13:975912. https://doi.org/10.3389/fendo.2022.975912CrossRefPubMed

Navarro-González J, Mora-Fernández C, de Fuentes M, García-Pérez J (2011) Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy: abstract: nature reviews nephrology. Nat Rev Nephrol 7(6):327–340PubMedCrossRef

Ni WJ, Tang LQ, Wei W (2015) Research progress in signalling pathway in diabetic nephropathy. Diabetes Metab Res Rev 31(3):221–233PubMedCrossRef

Ohiagu FO, Chikezie PC, Chikezie CM (2021) Pathophysiology of diabetes mellitus complications: metabolic events and control. Biomed Res Ther 8(3):4243–4257CrossRef

Oyebode OA, Jere SW, Houreld NN (2023) Current therapeutic modalities for the management of chronic diabetic wounds of the foot. J Diabetes Res 2023:1359537. https://doi.org/10.1155/2023/1359537CrossRefPubMedPubMedCentral

Parsamanesh N, Moossavi M, Bahrami A, Fereidouni M, Barreto G, Sahebkar A (2019) NLRP3 inflammasome as a treatment target in atherosclerosis: a focus on statin therapy. Int Immunopharmacol 73:146–155. https://doi.org/10.1016/j.intimp.2019.05.006CrossRefPubMed

Paschou SA, Shalit A, Gerontiti E, Athanasiadou KI, Kalampokas T, Psaltopoulou T et al (2024) Efficacy and safety of metformin during pregnancy: an update. Endocrine 83(2):259–269. https://doi.org/10.1007/s12020-023-03550-0CrossRefPubMed

Pasqua T, Pagliaro P, Rocca C, Angelone T, Penna C (2018) Role of NLRP-3 inflammasome in hypertension: a potential therapeutic target. Curr Pharm Biotechnol 19(9):708–714. https://doi.org/10.2174/1389201019666180808162011CrossRefPubMed

Peng Y, Ao M, Dong B, Jiang Y, Yu L, Chen Z et al (2021) Anti-inflammatory effects of curcumin in the inflammatory diseases: status, limitations and countermeasures. Drug des Devel Ther 15:4503–4525. https://doi.org/10.2147/DDDT.S327378CrossRefPubMedPubMedCentral

Pernicova I, Korbonits M (2014) Metformin–mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10(3):143–156. https://doi.org/10.1038/nrendo.2013.256CrossRefPubMed

Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association’s Standards of Medical Care in Diabetes Clinical Guideline (2020). Annals of Internal Medicine, 173(10), 813-821. https://doi.org/10.7326/M20-247

Qing L, Fu J, Wu P, Zhou Z, Yu F, Tang J (2019) Metformin induces the M2 macrophage polarization to accelerate the wound healing via regulating AMPK/mTOR/NLRP3 inflammasome singling pathway. Am J Transl Res 11(2):655–668PubMedPubMedCentral

Qiu Y-Y, Tang L-Q (2016) Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy. Pharmacol Res 114:251–264PubMedCrossRef

Rai RC, Bagul PK, Banerjee SK (2020) NLRP3 inflammasome drives inflammation in high fructose fed diabetic rat liver: effect of resveratrol and metformin. Life Sci 253:117727. https://doi.org/10.1016/j.lfs.2020.117727CrossRefPubMed

Rakoczy EP, Rahman ISA, Binz N, Li C-R, Vagaja NN, de Pinho M et al (2010) Characterization of a mouse model of hyperglycemia and retinal neovascularization. Am J Pathol 177(5):2659–2670PubMedPubMedCentralCrossRef

Ramachandran R, Manan A, Kim J, Choi S (2024) NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders. Exp Mol Med 56(7):1488–1500. https://doi.org/10.1038/s12276-024-01261-8CrossRefPubMedPubMedCentral

Ranjbar G, Mikhailidis DP, Sahebkar A (2019) Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box! (Review). Metabol Clin Experim. https://doi.org/10.1016/j.metabol.2019.154001CrossRef

Rashid M, Shahzad M, Mahmood S, Khan K (2019) Variability in the therapeutic response of metformin treatment in patients with Type 2 Diabetes mellitus. Pak J Med Sci 35(1):71–76. https://doi.org/10.12669/pjms.35.1.100CrossRefPubMedPubMedCentral

Razavi SM, Arab ZN, Niknejad A, Hosseini Y, Fouladi A, Khales SD et al (2024) Therapeutic effects of anti-diabetic drugs on traumatic brain injury. Diabetes Metab Syndr 18(2):102949. https://doi.org/10.1016/j.dsx.2024.102949CrossRefPubMed

Rena G, Pearson ER, Sakamoto K (2013) Molecular mechanism of action of metformin: old or new insights? Diabetologia 56:1898–1906PubMedPubMedCentralCrossRef

Rena G, Hardie DG, Pearson ER (2017) The mechanisms of action of metformin. Diabetologia 60(9):1577–1585PubMedPubMedCentralCrossRef

Rezaei S, Tabrizi R, Nowrouzi-Sohrabi P, Jalali M, Atkin SL, Al-Rasadi K et al (2021) GLP-1 receptor agonist effects on lipid and liver profiles in patients with nonalcoholic fatty liver disease: systematic review and meta-analysis (Review). Canadian J Gastroenterol Hepatol. https://doi.org/10.1155/2021/8936865CrossRef

Riehle C, Bauersachs J (2019) Of mice and men: models and mechanisms of diabetic cardiomyopathy. Basic Res Cardiol 114:1–22CrossRef

Saber S, El-Kader EMA (2021) Novel complementary coloprotective effects of metformin and MCC950 by modulating HSP90/NLRP3 interaction and inducing autophagy in rats. Inflammopharmacology 29(1):237–251. https://doi.org/10.1007/s10787-020-00730-6CrossRefPubMed

Saber S, Ghanim AMH, El-Ahwany E, El-Kader EMA (2020) Novel complementary antitumour effects of celastrol and metformin by targeting IκBκB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis. Cancer Chemother Pharmacol 85(2):331–343. https://doi.org/10.1007/s00280-020-04033-zCrossRefPubMed

Saberi-Karimian M, Keshvari M, Ghayour-Mobarhan M, Salehizadeh L, Rahmani S, Behnam B et al (2020) Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Complement Ther Med 49:102322. https://doi.org/10.1016/j.ctim.2020.102322CrossRefPubMed

Sadeghi M, Dehnavi S, Asadirad A, Xu S, Majeed M, Jamialahmadi T et al (2023) Curcumin and chemokines: mechanism of action and therapeutic potential in inflammatory diseases. Inflammopharmacology 31(3):1069–1093. https://doi.org/10.1007/s10787-023-01136-wCrossRefPubMedPubMedCentral

Sahebkar A, Henrotin Y (2016) Analgesic efficacy and safety of curcuminoids in clinical practice: a systematic review and meta-analysis of randomized controlled trials. Pain Med 17(6):1192–1202. https://doi.org/10.1093/pm/pnv024CrossRefPubMed

Sahebkar A (2010) Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril, 94(5):e75–e76; Author reply e77. https://doi.org/10.1016/j.fertnstert.2010.07.1071

Shaaban AA, Abdelhamid AM, Shaker ME, Cavalu S, Maghiar AM, Alsayegh AA et al (2022) Combining the HSP90 inhibitor TAS-116 with metformin effectively degrades the NLRP3 and attenuates inflammasome activation in rats: a new management paradigm for ulcerative colitis. Biomed Pharmacother 153:113247. https://doi.org/10.1016/j.biopha.2022.113247CrossRefPubMed

Shani M, Eviatar T, Komaneshter D, Vinker S (2018) Diabetic retinopathy–incidence and risk factors in a community setting-a longitudinal study. Scand J Prim Health Care 36(3):237–241PubMedPubMedCentralCrossRef

Shaw RJ, Lamia KA, Vasquez D, Koo S-H, Bardeesy N, DePinho RA et al (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310(5754):1642–1646PubMedPubMedCentralCrossRef

Shen Z, Zhou H, Li A, Wu T, Ji X, Guo L et al (2021) Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3. Aging (Albany NY) 13(18):22120–22133. https://doi.org/10.18632/aging.203464CrossRefPubMed

Shen Y, Cheng L, Xu M, Wang W, Wan Z, Xiong H et al (2023) SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis. Metabolism 146:155657. https://doi.org/10.1016/j.metabol.2023.155657CrossRefPubMed

Shi T, Lu H, Zhu J, Zhou X, He C, Li F et al (2023) Naturally derived dual dynamic crosslinked multifunctional hydrogel for diabetic wound healing. Compos B Eng 257:110687. https://doi.org/10.1016/j.compositesb.2023.110687CrossRef

Shishodia S, Sethi G, Aggarwal BB (2005) Curcumin: getting back to the roots. Ann N Y Acad Sci 1056:206–217. https://doi.org/10.1196/annals.1352.010CrossRefPubMed

Shitara Y, Nakamichi N, Norioka M, Shima H, Kato Y, Horie T (2013) Role of organic cation/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria. Toxicol Sci 132(1):32–42PubMedCrossRef

Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L et al (2017) Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes 66(2):241–255. https://doi.org/10.2337/db16-0806CrossRefPubMed

Song W, Wei L, Du Y, Wang Y, Jiang S (2018) Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF-κB/p38 signaling pathway in high-fat diet/streptozotocin-induced diabetic mice. Int Immunopharmacol 63:227–238PubMedCrossRef

Song Y, Wu Z, Zhao P (2022) The effects of metformin in the treatment of osteoarthritis: current perspectives. Front Pharmacol 13:952560. https://doi.org/10.3389/fphar.2022.952560CrossRefPubMedPubMedCentral

Sundelin E, Gormsen LC, Jensen JB, Vendelbo MH, Jakobsen S, Munk OL et al (2017) Genetic polymorphisms in organic cation transporter 1 attenuates hepatic metformin exposure in humans. Clin Pharmacol Ther 102(5):841–848. https://doi.org/10.1002/cpt.701CrossRefPubMed

Tan M (2000) Current treatment of insulin resistance in Type 2 Diabetes mellitus. Int J Clin Pract Suppl 113:54–62

Tan Y, Chen J, Jiang Y, Chen X, Li J, Chen B et al (2020) The anti-periodontitis action of metformin via targeting NLRP3 inflammasome. Arch Oral Biol 114:104692. https://doi.org/10.1016/j.archoralbio.2020.104692CrossRefPubMed

Tang G, Duan F, Li W, Wang Y, Zeng C, Hu J et al (2019) Metformin inhibited Nod-like receptor protein 3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE(-/-) mice. Biomed Pharmacother 119:109410. https://doi.org/10.1016/j.biopha.2019.109410CrossRefPubMed

Terman A, Kurz T, Gustafsson B, Brunk U (2006) Lysosomal labilization. IUBMB Life 58(9):531–539PubMedCrossRef

Tong G, Peng T, Chen Y, Sha L, Dai H, Xiang Y et al (2022) Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K/AKT/mTOR signaling pathway. Front Pharmacol 13:901559. https://doi.org/10.3389/fphar.2022.901559CrossRefPubMedPubMedCentral

Tourkochristou E, Aggeletopoulou I, Konstantakis C, Triantos C (2019) Role of NLRP3 inflammasome in inflammatory bowel diseases. World J Gastroenterol 25(33):4796–4804. https://doi.org/10.3748/wjg.v25.i33.4796CrossRefPubMedPubMedCentral

Triggle CR, Mohammed I, Bshesh K, Marei I, Ye K, Ding H et al (2022) Metformin: Is it a drug for all reasons and diseases? Metabolism 133:155223. https://doi.org/10.1016/j.metabol.2022.155223CrossRefPubMed

Tsuji G, Hashimoto-Hachiya A, Yen VH, Takemura M, Yumine A, Furue K et al (2020) Metformin inhibits IL-1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis. Cell Death Discov 6:11. https://doi.org/10.1038/s41420-020-0245-8CrossRefPubMedPubMedCentral

Tumur Z, Shimizu H, Enomoto A, Miyazaki H, Niwa T (2010) Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-ĸB activation. Am J Nephrol 31(5):435–441PubMedCrossRef

Unamuno X, Gómez-Ambrosi J, Ramírez B, Rodríguez A, Becerril S, Valentí V et al (2021) NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling. Cell Mol Immunol 18(4):1045–1057. https://doi.org/10.1038/s41423-019-0296-zCrossRefPubMed

Vinik AI, Casellini C, Parson HK, Colberg SR, Nevoret M-L (2018) Cardiac autonomic neuropathy in diabetes: a predictor of cardiometabolic events. Front Neurosci 12:591PubMedPubMedCentralCrossRef

Wang GS, Hoyte C (2019) Review of Biguanide (Metformin) toxicity. J Intens Care Med 34(11–12):863–876. https://doi.org/10.1177/0885066618793385CrossRef

Wang S, Li Y, Fan J, Zhang X, Luan J, Bian Q et al (2017a) Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation. Cell Death Dis 8(7):e2937–e2937PubMedPubMedCentralCrossRef

Wang S, Zhao X, Yang S, Chen B, Shi J (2017b) Salidroside alleviates high glucose-induced oxidative stress and extracellular matrix accumulation in rat glomerular mesangial cells by the TXNIP-NLRP3 inflammasome pathway. Chem Biol Interact 278:48–53PubMedCrossRef

Wang Y, Yu B, Wang L, Yang M, Xia Z, Wei W et al (2017c) Pioglitazone ameliorates glomerular NLRP3 inflammasome activation in apolipoprotein E knockout mice with diabetes mellitus. PLoS One 12(7):e0181248PubMedPubMedCentralCrossRef

Wang Z, Zhang S, Xiao Y, Zhang W, Wu S, Qin T et al (2020) NLRP3 inflammasome and inflammatory diseases. Oxid Med Cell Longev 2020:4063562. https://doi.org/10.1155/2020/4063562CrossRefPubMedPubMedCentral

Ward R, Li W, Abdul Y, Jackson L, Dong G, Jamil S et al (2019) NLRP3 inflammasome inhibition with MCC950 improves diabetes-mediated cognitive impairment and vasoneuronal remodeling after ischemia. Pharmacol Res 142:237–250. https://doi.org/10.1016/j.phrs.2019.01.035CrossRefPubMedPubMedCentral

Wei S, Ma W, Li X, Jiang C, Sun T, Li Y et al (2020) Involvement of ROS/NLRP3 inflammasome signaling pathway in doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol 20(5):507–519. https://doi.org/10.1007/s12012-020-09576-4CrossRefPubMed

Wilbon SS, Kolonin MG (2023) GLP1 receptor agonists-effects beyond obesity and diabetes. Cells. https://doi.org/10.3390/cells13010065CrossRefPubMedPubMedCentral

Xu A, Deng F, Chen Y, Kong Y, Pan L, Liao Q et al (2020) NF-kappaB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity. Biomed Pharmacother 130:110525. https://doi.org/10.1016/j.biopha.2020.110525CrossRefPubMed

Xu T, Wu X, Lu X, Liang Y, Mao Y, Loor JJ et al (2021) Metformin activated AMPK signaling contributes to the alleviation of LPS-induced inflammatory responses in bovine mammary epithelial cells. BMC Vet Res 17(1):97. https://doi.org/10.1186/s12917-021-02797-xCrossRefPubMedPubMedCentral

Yan J, Ding D, Feng G, Yang Y, Zhou Y, Ma L et al (2022) Metformin reduces chondrocyte pyroptosis in an osteoarthritis mouse model by inhibiting NLRP3 inflammasome activation. Exp Ther Med 23(3):222. https://doi.org/10.3892/etm.2022.11146CrossRefPubMedPubMedCentral

Yang F, Qin Y, Wang Y, Meng S, Xian H, Che H et al (2019a) Metformin inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent effects in diabetic cardiomyopathy. Int J Biol Sci 15(5):1010–1019. https://doi.org/10.7150/ijbs.29680CrossRefPubMedPubMedCentral

Yang Y, Wang H, Kouadir M, Song H, Shi F (2019b) Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis 10(2):128. https://doi.org/10.1038/s41419-019-1413-8CrossRefPubMedPubMedCentral

Yaribeygi H, Butler AE, Atkin SL, Katsiki N, Sahebkar A (2018a) Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways. J Cell Physiol 234(1):223–230. https://doi.org/10.1002/jcp.26851CrossRefPubMed

Yaribeygi H, Farrokhi FR, Rezaee R, Sahebkar A (2018b) Oxidative stress induces renal failure: a review of possible molecular pathways. J Cell Biochem 119(4):2990–2998PubMedCrossRef

Yaribeygi H, Atkin SL, Butler AE, Sahebkar A (2019a) Sodium-glucose cotransporter inhibitors and oxidative stress: An update. J Cell Physiol 234(4):3231–3237. https://doi.org/10.1002/jcp.26760CrossRefPubMed

Yaribeygi H, Atkin SL, Simental-Mendía LE, Barreto GE, Sahebkar A (2019b) Anti-inflammatory effects of resolvins in diabetic nephropathy: mechanistic pathways. J Cell Physiol 234(9):14873–14882PubMedCrossRef

Yaribeygi H, Butler AE, Sahebkar A (2019c) Aerobic exercise can modulate the underlying mechanisms involved in the development of diabetic complications. J Cell Physiol 234(8):12508–12515PubMedCrossRef

Yaribeygi H, Katsiki N, Butler AE, Sahebkar A (2019d) Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys. Drug Discov Today 24(1):256–262. https://doi.org/10.1016/j.drudis.2018.08.005CrossRefPubMed

Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A (2020) Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes. Life Sci 241:117152PubMedCrossRef

Yaribeygi H, Rashidy-Pour A, Atkin SL, Jamialahmadi T, Sahebkar A (2021) GLP-1 mimetics and cognition (Review). Life Sci. https://doi.org/10.1016/j.lfs.2020.118645CrossRefPubMed

Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3):556–564PubMedPubMedCentralCrossRef

Ye Y, Bajaj M, Yang H-C, Perez-Polo JR, Birnbaum Y (2017) SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther 31:119–132PubMedCrossRef

Yin Y, Chen F, Wang W, Wang H, Zhang X (2017) Resolvin D1 inhibits inflammatory response in STZ-induced diabetic retinopathy rats: Possible involvement of NLRP3 inflammasome and NF-κB signaling pathway. Mol vis 23:242PubMedPubMedCentral

Youssef ME, Abd El-Fattah EE, Abdelhamid AM, Eissa H, El-Ahwany E, Amin NA et al (2021) Interference with the AMPKα/mTOR/NLRP3 signaling and the IL-23/IL-17 axis effectively protects against the dextran sulfate sodium intoxication in rats: a new paradigm in empagliflozin and metformin reprofiling for the management of ulcerative colitis. Front Pharmacol 12:719984. https://doi.org/10.3389/fphar.2021.719984CrossRefPubMedPubMedCentral

Yu H, Lin L, Zhang Z, Zhang H, Hu H (2020) Targeting NF-kappaB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther 5(1):209. https://doi.org/10.1038/s41392-020-00312-6CrossRefPubMedPubMedCentral

Yu L, Hong W, Lu S, Li Y, Guan Y, Weng X et al (2022) The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: therapeutic targets and treatment. Front Pharmacol 13:780496. https://doi.org/10.3389/fphar.2022.780496CrossRefPubMedPubMedCentral

Yuan Y, Fan X, Guo Z, Zhou Z, Gao W (2022) Metformin protects against spinal cord injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway. Anal Cell Pathol (Amst) 2022:3634908. https://doi.org/10.1155/2022/3634908CrossRefPubMed

Zaccardi F, Webb DR, Yates T, Davies MJ (2016) Pathophysiology of type 1 and Type 2 Diabetes mellitus: a 90-year perspective. Postgrad Med J 92(1084):63–69. https://doi.org/10.1136/postgradmedj-2015-133281CrossRefPubMed

Zahid A, Li B, Kombe AJK, Jin T, Tao J (2019) Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol 10:2538. https://doi.org/10.3389/fimmu.2019.02538CrossRefPubMedPubMedCentral

Zake DM, Kurlovics J, Zaharenko L, Komasilovs V, Klovins J, Stalidzans E (2021) Physiologically based metformin pharmacokinetics model of mice and scale-up to humans for the estimation of concentrations in various tissues. PLoS One 16(4):e0249594. https://doi.org/10.1371/journal.pone.0249594CrossRefPubMedPubMedCentral

Zhang BB, Zhou G, Li C (2009) AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9(5):407–416PubMedCrossRef

Zhang L, Lu L, Zhong X, Yue Y, Hong Y, Li Y et al (2019) Metformin reduced NLRP3 inflammasome activity in Ox-LDL stimulated macrophages through adenosine monophosphate activated protein kinase and protein phosphatase 2A. Eur J Pharmacol 852:99–106. https://doi.org/10.1016/j.ejphar.2019.03.006CrossRefPubMed

Zhang J, Huang L, Shi X, Yang L, Hua F, Ma J et al (2020) Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway. Aging (Albany NY) 12(23):24270–24287. https://doi.org/10.18632/aging.202143CrossRefPubMed

Zhang Y, Liu W, Zhong Y, Li Q, Wu M, Yang L et al (2021) Metformin corrects glucose metabolism reprogramming and NLRP3 inflammasome-induced pyroptosis via inhibiting the TLR4/NF-κB/PFKFB3 signaling in trophoblasts: implication for a potential therapy of preeclampsia. Oxid Med Cell Longev 2021:1806344. https://doi.org/10.1155/2021/1806344CrossRefPubMedPubMedCentral

Zhang T, Wang Y, Yao W, Chen Y, Zhang D, Gao Y et al (2022a) Metformin antagonizes nickel-refining fumes-induced cell pyroptosis via Nrf2/GOLPH3 pathway in vitro and in vivo. Ecotoxicol Environ Saf 247:114233. https://doi.org/10.1016/j.ecoenv.2022.114233CrossRefPubMed

Zhang Y, Zhang H, Li S, Huang K, Jiang L, Wang Y (2022b) Metformin alleviates LPS-induced acute lung injury by regulating the SIRT1/NF-κB/NLRP3 pathway and inhibiting endothelial cell pyroptosis. Front Pharmacol 13:801337. https://doi.org/10.3389/fphar.2022.801337CrossRefPubMedPubMedCentral

Zhang X, Wang Z, Zheng Y, Yu Q, Zeng M, Bai L et al (2023) Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review). Int J Mol Med. https://doi.org/10.3892/ijmm.2023.5238CrossRefPubMedPubMedCentral

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108(8):1167–1174. https://doi.org/10.1172/jci13505CrossRefPubMedPubMedCentral

Zhou M, Xia L, Wang J (2007) Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 35(10):1956–1962. https://doi.org/10.1124/dmd.107.015495CrossRefPubMed

Zhou SX, Huo DM, He XY, Yu P, Xiao YH, Ou CL et al (2018) High glucose/lysophosphatidylcholine levels stimulate extracellular matrix deposition in diabetic nephropathy via platelet-activating factor receptor. Mol Med Rep 17(2):2366–2372PubMed

Zhou X, Zhang P, Wang Q, Ji N, Xia S, Ding Y et al (2019) Metformin ameliorates experimental diabetic periodontitis independently of mammalian target of rapamycin (mTOR) inhibition by reducing NIMA-related kinase 7 (Nek7) expression. J Periodontol 90(9):1032–1042. https://doi.org/10.1002/jper.18-0528CrossRefPubMed

Zhou X, Wang Q, Nie L, Zhang P, Zhao P, Yuan Q et al (2020) Metformin ameliorates the NLPP3 inflammasome mediated pyroptosis by inhibiting the expression of NEK7 in diabetic periodontitis. Arch Oral Biol 116:104763. https://doi.org/10.1016/j.archoralbio.2020.104763CrossRefPubMed

Podcast | Sexual health in older age

Springer Medicine

NLRP3 inflammasomes pathway: a key target for Metformin

Abstract

Podcast | Sexual health in older age

Springer Medicine

Abstract

Please log in to get access to this content